Suppr超能文献

相似文献

1
Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease.
JAMA Ophthalmol. 2015 Mar;133(3):290-6. doi: 10.1001/jamaophthalmol.2014.5103.
2
Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131.
J Clin Endocrinol Metab. 2009 Oct;94(10):3700-7. doi: 10.1210/jc.2009-0747. Epub 2009 Sep 1.
3
Management of Graves Thyroidal and Extrathyroidal Disease: An Update.
J Clin Endocrinol Metab. 2020 Dec 1;105(12):3704-20. doi: 10.1210/clinem/dgaa646.
4
Comparative Effectiveness of Treatment Choices for Graves' Hyperthyroidism: A Historical Cohort Study.
Thyroid. 2017 Apr;27(4):497-505. doi: 10.1089/thy.2016.0343. Epub 2017 Feb 6.
5
Chronology of Graves' ophthalmopathy in an incidence cohort.
Am J Ophthalmol. 1996 Apr;121(4):426-34. doi: 10.1016/s0002-9394(14)70439-8.
7
Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves Disease.
J Clin Endocrinol Metab. 2021 Apr 23;106(5):1325-1332. doi: 10.1210/clinem/dgab070.
8
2022 Update on Clinical Management of Graves Disease and Thyroid Eye Disease.
Endocrinol Metab Clin North Am. 2022 Jun;51(2):287-304. doi: 10.1016/j.ecl.2021.12.004. Epub 2022 May 11.
9
Current management of thyroid-associated ophthalmopathy in Europe. Results of an international survey.
Clin Endocrinol (Oxf). 1998 Jul;49(1):21-8. doi: 10.1046/j.1365-2265.1998.00487.x.

引用本文的文献

3
Insight into the metabolic shifts in Graves' hyperthyroidism: a study of acylcarnitine and lipid profiles.
Eur Thyroid J. 2025 Jun 11;14(3). doi: 10.1530/ETJ-25-0004. Print 2025 Jun 1.
4
Preventing Thyroid Eye Disease with Statins: Evidence from a Meta-Analysis.
Cureus. 2025 May 19;17(5):e84388. doi: 10.7759/cureus.84388. eCollection 2025 May.
5
Molecular pathway and mechanism responsible for the progress of thyroid-associated orbitopathy.
Int Ophthalmol. 2025 May 17;45(1):197. doi: 10.1007/s10792-025-03564-9.
6
Statins and Thyroid Eye Disease: A Propensity Score-Matched Retrospective Cohort Analysis.
Cureus. 2025 Apr 30;17(4):e83243. doi: 10.7759/cureus.83243. eCollection 2025 Apr.
8
Novel perspectives on the pharmacological treatment of thyroid-associated ophthalmopathy.
Front Endocrinol (Lausanne). 2025 Jan 13;15:1469268. doi: 10.3389/fendo.2024.1469268. eCollection 2024.
9
Simvastatin-Induced Ferroptosis in Orbital Fibroblasts in Graves' Ophthalmopathy.
Invest Ophthalmol Vis Sci. 2025 Jan 2;66(1):56. doi: 10.1167/iovs.66.1.56.
10
The relationship between cholesterol levels and thyroid eye disease.
Eur Thyroid J. 2025 Feb 3;14(1). doi: 10.1530/ETJ-24-0133. Print 2025 Feb 1.

本文引用的文献

2
Clinical relevance of thyroid-stimulating immunoglobulins in graves' ophthalmopathy.
Ophthalmology. 2011 Nov;118(11):2279-85. doi: 10.1016/j.ophtha.2011.03.030.
4
The relationship between components of metabolic syndrome and open-angle glaucoma.
Ophthalmology. 2011 Jul;118(7):1318-26. doi: 10.1016/j.ophtha.2010.11.022. Epub 2011 Apr 9.
5
Differences in rates of glaucoma among Asian Americans and other racial groups, and among various Asian ethnic groups.
Ophthalmology. 2011 Jun;118(6):1031-7. doi: 10.1016/j.ophtha.2010.10.024. Epub 2011 Feb 18.
6
Statin use in patients with asthma: a nationwide population-based study.
Eur J Clin Invest. 2011 May;41(5):507-12. doi: 10.1111/j.1365-2362.2010.02434.x. Epub 2010 Dec 3.
8
Statins as emerging treatments for asthma and chronic obstructive pulmonary disease.
Expert Rev Respir Med. 2008 Jun;2(3):329-35. doi: 10.1586/17476348.2.3.329.
9
Immunopathogenesis of thyroid eye disease: emerging paradigms.
Surv Ophthalmol. 2010 May-Jun;55(3):215-26. doi: 10.1016/j.survophthal.2009.06.009.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验